Angel Studios, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Angel Studios, Inc. (ANGX) on December 5, 2025. The report details the entry into a material definitive agreement to establish an "at-the-market" equity offering program. The Company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, or debt levels. The primary financial metric disclosed is the authorization to raise up to $150,000,000 through the sale of Class A common stock.
Material Changes and Agreements
On December 5, 2025, the Company entered into an Equity Distribution Agreement with four sales agents: Oppenheimer & Co. Inc., TCBI Securities, Inc. (Texas Capital Securities), Maxim Group LLC, and Roth Capital Partners, LLC. Key terms include:
- Offering Size: Up to $150 million in aggregate offering price.
- Method: At-the-market offerings under an effective Form S-3 shelf registration statement (declared effective December 4, 2025).
- Compensation: Sales agents receive a commission of up to 3.0% of the gross sales price per share.
- Legal Fees: The Company agreed to reimburse agents for counsel fees up to $100,000 for establishment and $15,000 quarterly thereafter.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, management commentary on future performance, or a discussion of general business risks. The primary contingency noted is that sales of shares are subject to instructions from the Company regarding price, time, and size limits. The report explicitly states it does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the current market price of ANGX to assess potential dilution from the $150 million offering.
- Review the full text of the Equity Distribution Agreement (Exhibit 1.1) for specific termination provisions and conditions.
- Confirm the status of the underlying Form S-3 registration statement (File No. 333-291514) and any subsequent prospectus supplements.
- Monitor future filings for actual sales volumes and proceeds generated under this program.